Clinical Infectious Diseases

Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus..  74:95-104. 2022

Effectiveness of 13-valent pneumococcal conjugate vaccine against medically-attended lower respiratory tract infection and pneumonia among older adults. 2021

Oral streptococci expressing pneumococci-like cross-reactive capsule types can affect WHO recommended pneumococcal carriage procedure. 2021

Decreasing High-risk Exposures for Healthcare Workers through Universal Masking and Universal Severe Acute Respiratory Syndrome Coronavirus 2 Testing on Entry to a Tertiary Care Facility.  73:E3113-E3115. 2021

The Need for New Tools for Syphilis Diagnosis and Management.  73:E3259-E3260. 2021

The national academies report on sexually transmitted infections: Implications for clinical training, licensing, and practice guidelines.  73:1711-1716. 2021

High Prevalence of Anal High-Grade Squamous Intraepithelial Lesions, and Prevention Through Human Papillomavirus Vaccination, in Young Men Who Have Sex With Men Living With Human Immunodeficiency Virus.  73:1388-1396. 2021

Candidatus Mycoplasma haemohominis: Emerging Infection in New Caledonia.  73:e1454-e1455. 2021

Cost-effectiveness of Frequent HIV Screening Among High-risk Young Men Who Have Sex With Men in the United States.  73:e1927-e1935. 2021

Incident Non-AIDS Comorbidity Burden Among Women With or at Risk for Human Immunodeficiency Virus in the United States.  73:e2059-e2069. 2021

MSG07: An International Cohort Study Comparing Epidemiology and Outcomes of Patients With Cryptococcus neoformans or Cryptococcus gattii Infections.  73:1133-1141. 2021

Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada.  73:e2234-e2242. 2021

The Human Immunodeficiency Virus (HIV) Index: Using a Patient-Reported Outcome on Engagement in HIV Care to Explain Suboptimal Retention in Care and Virologic Control.  73:e2175-e2183. 2021

We Thought We Created a Safety Net. We Were Wrong.  73:e1658-e1660. 2021

Efficacy and Safety of Single Oral Dosing of Secnidazole for Trichomoniasis in Women: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Delayed-Treatment Study.  73:e1282-e1289. 2021

Epidemiology, Natural History, Diagnosis, and Treatment of Trichomonas vaginalis in Men.  73:1119-1124. 2021

TREAT-B: Simple low-cost diagnostic score for when to treat hepatitis B.  73:E1078-E1079. 2021

Treatment of Male Sexual Partners of Women With Bacterial Vaginosis: A Randomized, Double-Blind, Placebo-Controlled Trial.  73:e672-e679. 2021

Rapid Antiretroviral Therapy: Time for a new Standard of Care.  73:134-136. 2021

COVID-19-Lessons Learned and Questions Remaining.  72:2225-2240. 2021

It Is Time to Focus on Asymptomatic Tuberculosis.  72:E1044-E1046. 2021

Major Adverse Cardiovascular Events during Invasive Pneumococcal Disease Are Serotype Dependent.  72:E711-E719. 2021

Timing of Antiretroviral Therapy Initiation and Risk of Cancer among Persons Living with Human Immunodeficiency Virus.  72:1900-1909. 2021

Implications of Efavirenz Pharmacogenetics When Switching From Efavirenz- to Dolutegravir-containing Antiretroviral Regimens.  72:1820-1822. 2021

Primary HPV and Molecular Cervical Cancer Screening in US Women Living With Human Immunodeficiency Virus.  72:1529-1537. 2021

The Prevalence and Burden of Non-AIDS Comorbidities Among Women Living With or at Risk for Human Immunodeficiency Virus Infection in the United States.  72:1301-1311. 2021

Comparing Nasopharyngeal and Midturbinate Nasal Swab Testing for the Identification of Severe Acute Respiratory Syndrome Coronavirus 2.  72:1253-1255. 2021

Cryptococcal Antigen in Serum and Cerebrospinal Fluid for Detecting Cryptococcal Meningitis in Adults Living with Human Immunodeficiency Virus: Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies.  72:1268-1278. 2021

The Evidence Supporting the Revised EORTC/MSGERC Definitions for Invasive Fungal Infections.  72:S77-S78. 2021

"rapid Start" Treatment to End the (Other) Epidemic: Walking the Tightrope without a Net.  72:479-481. 2021

Breast Milk and COVID-19: What Do We Know?.  72:131-132. 2021

Reply to simon and to eljaaly and nix.  63:287-288. 2021

Reply to Luppi et al.  71:3266. 2020

Clinic-level factors associated with retention in care among people living with human immunodeficiency virus in a multisite US Cohort, 2010–2016.  71:2592-2598. 2020

Longitudinal care cascade outcomes among people eligible for antiretroviral therapy who are newly linking to care in Zambia: A multistate analysis.  71:E561-E570. 2020

Prevalence of mycoplasma genitalium infection, antimicrobial resistance mutations, and symptom resolution following treatment of urethritis.  71:E624-E632. 2020

Reply to Herbrecht et al.  71:2774-2775. 2020

Intersecting Epidemics: Incident Syphilis and Drug Use in Women Living with Human Immunodeficiency Virus in the United States (2005-2016).  71:2405-2413. 2020

Reply to Mafaciolli and Pasqualotto.  71:2542-2543. 2020

Food insecurity is associated with lower levels of antiretroviral drug concentrations in hair among a cohort of women living with human immunodeficiency virus in the United States.  71:1517-1523. 2020

Revision and update of the consensus definitions of invasive fungal disease from the european organization for research and treatment of cancer and the mycoses study group education and research consortium.  71:1367-1376. 2020

Viral kinetics and resistance development in children treated with neuraminidase inhibitors: The influenza resistance information study (IRIS).  71:1186-1194. 2020

Resistance of influenza virus to antiviral medications.  71:1092-1094. 2020

Meningoencephalitis due to spotted fever rickettsioses, including rocky mountain spotted fever.  71:188-195. 2020

Outpatient urinary tract infections in an era of virtual healthcare: Trends from 2008 to 2017.  71:100-108. 2020

What's All This Fuss I Hear About Viral "Blips"?.  70:2710-2711. 2020

Making the most of point-of-care testing for sexually transmitted diseases.  70:1824-1825. 2020

Contribution of congenital cytomegalovirus infection to permanent hearing loss in a highly seropositive population: The brazilian cytomegalovirus hearing and maternal secondary infection study.  70:1379-1384. 2020

Development of new antimicrobials for urogenital gonorrhea therapy: Clinical trial design considerations.  70:1495-1500. 2020

Reply to Tascini et al.  70:1523-1524. 2020

Association of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia with Anal Cancer Risk in Persons Living with HIV in the United States and Canada.  70:1176-1185. 2020

Histoplasmosis: Time to Redraw the Map and Up Our Game.  70:1011-1013. 2020

Blood transcriptomic stratification of short-term risk in contacts of tuberculosis.  70:731-737. 2020

Impact of abstinence and of reducing illicit drug use without abstinence on human immunodeficiency virus viral load.  70:867-874. 2020

Changes in Bone Mass after Discontinuation of Preexposure Prophylaxis with Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex with Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113.  70:687-691. 2020

Letter to the Editor.  70:718-719. 2020

A multicenter, longitudinal cohort study of cryptococcosis in human immunodeficiency virus-negative people in the United States.  70:252-261. 2020

Maternal Cytomegalovirus Infection and Fetal Impairment: Uncertainty Remains.  70:174. 2020

Trichomonas vaginalis Virus among Women with Trichomoniasis and Associations with Demographics, Clinical Outcomes, and Metronidazole Resistance.  69:2170-2176. 2019

Prevalence of Congenital Cytomegalovirus Infection and Associated Risk of in Utero Human Immunodeficiency Virus (HIV) Acquisition in a High-HIV Prevalence Setting, South Africa.  69:1789-1796. 2019

Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) after Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells.  69:1345-1352. 2019

Determining the Origins of Human Immunodeficiency Virus Type 1 Drug-resistant Minority Variants in People Who Are Recently Infected Using Phylogenetic Reconstruction.  69:1136-1143. 2019

Immunogenicity and Viral Shedding of Russian-Backbone, Seasonal, Trivalent, Live, Attenuated Influenza Vaccine in a Phase II, Randomized, Placebo-Controlled Trial among Preschool-Aged Children in Urban Bangladesh.  69:777-785. 2019

The Effect of Preexisting Immunity on Virus Detection and Immune Responses in a Phase II, Randomized Trial of a Russian-Backbone, Live, Attenuated Influenza Vaccine in Bangladeshi Children.  69:786-794. 2019

Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial.  68:1981-1989. 2019

Plasma 25-Hydroxyvitamin D and the Longitudinal Risk of Sepsis in the REGARDS Cohort.  68:1926-1931. 2019

Impact of infectious disease consultation on clinical management and mortality in patients with candidemia.  68:1585-1587. 2019

Phase 1 Safety and Pharmacokinetics Study of MK-2048/Vicriviroc (MK-4176)/MK-2048A Intravaginal Rings.  68:1136-1143. 2019

Phase 2a Safety, Pharmacokinetics, and Acceptability of Dapivirine Vaginal Rings in US Postmenopausal Women.  68:1144-1151. 2019

A 9-Point Risk Assessment for Patients Who Inject Drugs and Require Intravenous Antibiotics: Focusing Inpatient Resources on Patients at Greatest Risk of Ongoing Drug Use.  68:1041-1043. 2019

Safety and efficacy of a novel vaginal anti-infective, TOL-463, in the treatment of bacterial vaginosis and vulvovaginal candidiasis: A randomized, single-blind, phase 2, controlled trial.  68:803-809. 2019

Depressive Symptoms and Engagement in Human Immunodeficiency Virus Care Following Antiretroviral Therapy Initiation.  68:475-481. 2019

Molecular-based testing for sexually transmitted infections using samples previously collected for vaginitis diagnosis.  68:375-381. 2019

Increased dolutegravir peak concentrations in people living with human immunodeficiency virus aged 60 and over, and analysis of sleep quality and cognition.  68:87-95. 2019

The North-South divide: Substance use risk, care engagement, and viral suppression among hospitalized human immunodeficiency virus-infected patients in 11 US cities.  68:146-149. 2019

Cumulative burden of depression and all-cause mortality in women living with human immunodeficiency virus.  67:1575-1581. 2018

A Brief History of Evolving Diagnostics and Therapy for Gonorrhea: Lessons Learned.  67:1294-1299. 2018

Application of a Multistate Model to Evaluate Visit Burden and Patient Stability to Improve Sustainability of Human Immunodeficiency Virus Treatment in Zambia.  67:1269-1277. 2018

No Impact of Hepatitis B Virus Infection on Early Mortality among Human Immunodeficiency Virus-Infected Patients in Southern Africa.  67:1310-1311. 2018

Large Outbreak of Hepatitis C Virus Associated with Drug Diversion by a Healthcare Technician.  67:845-853. 2018

Cytomegalovirus Shedding in Seropositive Pregnant Women from a High-Seroprevalence Population: The Brazilian Cytomegalovirus Hearing and Maternal Secondary Infection Study.  67:743-750. 2018

Why does trichomonas vaginalis continue to be a "neglected" sexually transmitted infection?.  67:218-220. 2018

A silent epidemic: The prevalence, incidence and persistence of mycoplasma genitalium among young, asymptomatic high-risk women in the United States.  67:73-79. 2018

Association of Neighborhood Socioeconomic Status with Risk of Infection and Sepsis.  66:1940-1947. 2018

ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants with HIV-1 RNA <500000 Copies/mL.  66:1689-1697. 2018

Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel.  66:1678-1686. 2018

Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial.  66:1794-1797. 2018

Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials.  66:1492-1500. 2018

Multimorbidity among Persons Living with Human Immunodeficiency Virus in the United States.  66:1230-1238. 2018

Management of an Outbreak of Exophiala dermatitidis Bloodstream Infections at an Outpatient Oncology Clinic.  66:959-962. 2018

High prevalence of multidrug-resistant mycoplasma genitalium in human immunodeficiency virus-infected men who have sex with men in Alabama.  66:796-798. 2018

Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis among Adolescent and Young Men Who Have Sex with Men in the United States.  66:213-219. 2018

Improved Retention with 6-Month Clinic Return Intervals for Stable Human Immunodeficiency Virus-Infected Patients in Zambia.  66:237-243. 2018

Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults with Human Immunodeficiency Virus Infection Being Treated with Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial.  66:220-228. 2018

Outbreak of Foodborne Botulism in an Immigrant Community: Overcoming Delayed Disease Recognition, Ambiguous Epidemiologic Links, and Cultural Barriers to Identify the Cause.  66:S82-S84. 2017

The Impact of Statin and Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy on Cognitive Function in Adults with Human Immunodeficiency Virus Infection.  65:2042-2049. 2017

Reproductive Aging and Hepatic Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women.  65:1695-1702. 2017

Mycoplasma hominis Infections Transmitted Through Amniotic Tissue Product.  65:1152-1158. 2017

CD4:CD8 Ratio and CD8 Count as prognostic markers for mortality in human immunodeficiency virus-infected patients on antiretroviral therapy: The antiretroviral therapy cohort collaboration (ART-CC).  65:959-966. 2017

Continued evolution of gonococcal antimicrobial resistance.  65:924-926. 2017

Cancer-Attributable Mortality among People with Treated Human Immunodeficiency Virus Infection in North America.  65:636-643. 2017

Risk of Acute Coronary Heart Disease after Sepsis Hospitalization in the REasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort.  65:29-36. 2017

Antiretroviral therapy initiation and changes in self-reported depression.  64:1791-1794. 2017

Continuum of care for hepatitis C virus among patients diagnosed in the emergency department setting.  64:1540-1546. 2017

Incident AIDS or death after initiation of human immunodeficiency virus treatment regimens including raltegravir or efavirenz among adults in the United States.  64:1591-1596. 2017

Impact of Antiretroviral Therapy on Liver Fibrosis among Human Immunodeficiency Virus-Infected Adults with and Without HBV Coinfection in Zambia.  64:1343-1349. 2017

Diffuse white matter signal abnormalities on magnetic resonance imaging are associated with human immunodeficiency virus type 1 viral escape in the central nervous system among patients with neurological symptoms.  64:1059-1065. 2017

Association of Diabetes and Insulin Therapy With Risk of Hospitalization for Infection and 28-Day Mortality Risk..  64:435-442. 2017

Association of diabetes and insulin therapy with risk of hospitalization for infection and 28-day mortality risk.  64:435-442. 2017

Decline in bone mass with tenofovir disoproxil fumarate/emtricitabine is associated with hormonal changes in the absence of renal impairment when used by HIV-uninfected adolescent boys and young men for HIV preexposure prophylaxis.  64:317-325. 2017

Angiostrongylus cantonensis infection: A cause of fever of unknown origin in pediatric patients.  63:1475-1478. 2016

Kaposi sarcoma risk in HIV-infected children and adolescents on combination antiretroviral therapy from sub-Saharan Africa, Europe, and Asia.  63:1245-1253. 2016

Durable Viral Suppression and Transmission Risk Potential among Persons with Diagnosed HIV Infection: United States, 2012-2013.  63:976-983. 2016

The Veterans Aging Cohort Study (VACS) Index and Neurocognitive Change: A Longitudinal Study.  63:694-702. 2016

Successful re-treatment of hepatitis C virus in patients coinfected with HIV Who relapsed after 12 weeks of ledipasvir/sofosbuvir.  63:528-531. 2016

Editorial Commentary: Affordable Care Act, Medicaid Expansion ... or Not: Ryan White Care Act Remains Essential for Access and Equity.  63:404-406. 2016

Inpatient mortality among solid organ transplant recipients hospitalized for sepsis and severe sepsis.  63:186-194. 2016

Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy among HIV-infected Patients Followed for up to 15 Years after Start of Treatment: Collaborative Cohort Study.  62:1571-1577. 2016

Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with vibrio cholerae O1 El Tor.  62:1329-1335. 2016

Emergency Department Screening for Hepatitis C Virus: Geographic Reach and Spatial Clustering in Central Alabama.  62:613-616. 2016

Home Screening for Bacterial Vaginosis to Prevent Sexually Transmitted Diseases.  62:531-536. 2016

Randomized controlled trial to compare immunogenicity of standard-dose intramuscular versus intradermal trivalent inactivated influenza vaccine in HIV-infected men who have sex with men in Bangkok, Thailand.  62:383-391. 2016

A Review of Evidence-Based Care of Symptomatic Trichomoniasis and Asymptomatic Trichomonas vaginalis Infections.  61:S837-S848. 2015

Diagnosis and Management of Uncomplicated Chlamydia trachomatis Infections in Adolescents and Adults: Summary of Evidence Reviewed for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines.  61:S774-S784. 2015

Immunization costs and programmatic barriers at an urban HIV clinic.  61:1726-1731. 2015

Cervical Precancer Risk in HIV-Infected Women Who Test Positive for Oncogenic Human Papillomavirus Despite a Normal Pap Test.  61:1573-1581. 2015

Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.  62:e1-e50. 2015

Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.  62:409-417. 2015

Host-directed therapies for tackling multi-drug resistant tuberculosis: Learning from the pasteur-bechamp debates.  61:1432-1438. 2015

Live animal markets in Minnesota: A potential source for emergence of novel influenza a viruses and interspecies transmission.  61:1355-1362. 2015

Aspergillus Polymerase Chain Reaction: Systematic Review of Evidence for Clinical Use in Comparison with Antigen Testing.  61:1293-1303. 2015

A Phase 2 Trial of Oral Solithromycin 1200 mg or 1000 mg as Single-Dose Oral Therapy for Uncomplicated Gonorrhea.  61:1043-1048. 2015

Age at Entry into Care, Timing of Antiretroviral Therapy Initiation, and 10-Year Mortality among HIV-Seropositive Adults in the United States.  61:1189-1195. 2015

Less Bone Loss with Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.  61:1179-1188. 2015

Extended-release niacin versus fenofibrate in HIV-infected participants with low high-density lipoprotein cholesterol: Effects on endothelial function, lipoproteins, and inflammation.  61:840-849. 2015

Herpes simplex encephalitis: Lack of clinical benefit of long-term valacyclovir therapy.  61:683-691. 2015

Biofilms: An Underappreciated Mechanism of Treatment Failure and Recurrence in Vaginal Infections.  61:601-606. 2015

Reply to Bauer and Goff.  61:487-488. 2015

Editorial Commentary: Getting Smart in How We Pay for HCV Drugs: KAOS vs CONTROL.  61:169-170. 2015

Dynamic visual display of treatment response in HIV-infected adults.  61:e1-e4. 2015

Predicting risk of endocarditis using a clinical tool (PREDICT): Scoring system to guide use of echocardiography in the management of Staphylococcus aureus bacteremia.  61:18-28. 2015

Ten-year survival by race/ethnicity and sex among treated, HIV-infected adults in the United States.  60:1700-1707. 2015

Use of clinical and neuroimaging characteristics to distinguish temporal lobe herpes simplex encephalitis from its mimics.  60:1377-1383. 2015

Editorial commentary: Women who have sex with women: A unique population for studying the pathogenesis of bacterial vaginosis.  60:1054-1056. 2015

End-stage renal disease among HIV-infected adults in North America.  60:941-949. 2015

T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: A clinical trial.  60:892-899. 2015

Waning efficacy of the herpes zoster vaccine.  60:910-911. 2015

Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: A Collaborative Study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group.  60:713-720. 2015

Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.  60:703-712. 2015

Eosinophil-associated processes underlie differences in clinical presentation of loiasis between temporary residents and those indigenous to loa-endemic areas.  60:55-63. 2015

Fixing a hole in the HIV safety net.  60:126-127. 2015

Chronic hepatitis B virus coinfection is associated with renal impairment among zambian HIV-infected adults.  59:1757-1760. 2014

Current practices of screening for incident hepatitis C virus (HCV) infection among HIV-infected, HCV-uninfected individuals in primary care.  59:1686-1693. 2014

An expanded role for therapeutic lumbar punctures in newly diagnosed aids-associated cryptococcal meningitis?.  59:1615-1617. 2014

Beyond core indicators of retention in HIV care: Missed clinic visits are independently associated with all-cause mortality.  59:1471-1479. 2014

The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea.  59:1083-1091. 2014

Added benefit of nucleic acid amplification testing for the diagnosis of Trichomonas vaginalis among men and women attending a sexually transmitted diseases clinic.  59:834-841. 2014

National estimates of healthcare utilization by individuals with hepatitis C virus infection in the United States.  59:755-764. 2014

Enhanced personal contact with HIV patients improves retention in primary care: A randomized trial in 6 US HIV clinics.  59:725-734. 2014

Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients.  59:287-297. 2014

Lymphoma immune reconstitution inflammatory syndrome in the center for AIDS research network of integrated clinical systems cohort.  59:279-286. 2014

Reply to rapose.  59:316-317. 2014

Reversible blindness in cryptococcal meningitis with normal intracranial pressure: Case report and review of the literature.  59:310-313. 2014

Addressing the achilles' heel in the HIV care continuum for the success of a test-and-treat strategy to achieve an AIDS-free generation.  59. 2014

HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy.  58:1599-1606. 2014

Birth prevalence of congenital cytomegalovirus among infants of HIV-infected women on prenatal antiretroviral prophylaxis in South Africa.  58:1467-1472. 2014

Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.  58:1473-1480. 2014

Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery.  58:1312-1321. 2014

MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting.  58:1219-1226. 2014

Antibiotic hypersensitivity reactions and approaches to desensitization.  58:1140-1148. 2014

Disparities in the quality of HIV care when using US department of health and human services indicators.  58:1185-1189. 2014

Erratum: Global assessment of resistance to neuraminidase inhibitors, 2008-2011: The Influenza Resistance Information Study (IRIS) (Clinical Infectious Diseases (2013) 56 (1197-205)).  58:1203. 2014

Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.  58:413-422. 2014

Church attendance in men who have sex with men diagnosed with HIV is associated with later presentation for HIV care.  58:295-299. 2014

Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials.  58:1297-1307. 2014

Case definitions, diagnostic algorithms, and priorities in encephalitis: Consensus statement of the international encephalitis consortium.  57:1114-1128. 2013

Reply to Yang et al.  57:1212-1213. 2013

The state of engagement in HIV care in the United States: From cascade to continuum to control.  57:1164-1171. 2013

A systematic review and meta-regression of temporal trends in adult CD4⁺ cell count at presentation to HIV care, 1992-2011.  57:1027-1037. 2013

Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women.  57:735-744. 2013

Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy.  57:756-764. 2013

Clinical reasoning for the infectious disease specialist: A primer to recognize cognitive biases.  57:573-578. 2013

Human infections with influenza A(H3N2) variant virus in the United States, 2011-2012.  57. 2013

Influence of geographical origin and ethnicity on mortality in patients on antiretroviral therapy in Canada, Europe, and the United States.  56:1800-1809. 2013

Syphilis treatment response among HIV-discordant couples in Zambia and Rwanda.  56:1829-1837. 2013

Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death.  56:1471-1479. 2013

Global assessment of resistance to neuraminidase inhibitors, 2008-2011: The influenza resistance information study (IRIS).  56:1197-1205. 2013

Trends and disparities in antiretroviral therapy initiation and Virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009.  56:1174-1182. 2013

Erratum: Changing epidemiology of herpes simplex virus infections (Clinical Infectious Diseases (2013) 56 (352-353)).  56:1066. 2013

Editorial Commentary: Sexual networks, sex hormones, and recurrent bacterial vaginosis: Not such strange bedfellows.  56:787-879. 2013

Cardiac disease in adolescents with delayed diagnosis of vertically acquired HIV infection.  56:576-582. 2013

Editorial commentary: Changing Epidemiology of Herpes Simplex Virus Infections.  56:352-353. 2013

Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women.  56:344-351. 2013

Response to therapy following retreatment of serofast early syphilis patients with benzathine penicillin.  56:420-422. 2013

Influence of the timing of cardiac surgery on the outcome of patients with infective endocarditis and stroke.  56:209-217. 2013

Near-universal prevalence of pneumocystis and associated increase in mucus in the lungs of infants with sudden unexpected death.  56:171-179. 2013

Congenital cytomegalovirus infection: audiologic outcome..  57 Suppl 4. 2013

Congenital cytomegalovirus infection: clinical outcome..  57 Suppl 4. 2013

Environmental risk factors for pneumocystis pneumonia hospitalizations in HIV patients.  56:74-81. 2013

Editorial commentary: A syphilis wish list: Better data, better tests.  55:1623-1624. 2012

Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients.  55:1550-1557. 2012

Editorial commentary: Viva no différence!.  55:1252-1254. 2012

Novel pneumococcal serotypes 6C and 6D: Anomaly or harbinger.  55:1379-1386. 2012

A low-effort, clinic-wide intervention improves attendance for HIV primary care.  55:1124-1134. 2012

Clinical scoring for risk of resistant organisms in pneumonia: Right idea, wrong interpretation.  55:749-750. 2012

Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease.  55. 2012

Reply to Anaissie and Nucci and to Cisneros et al.  55:894-895. 2012

Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent trials network study 021B.  55:461-468. 2012

Chronic lung disease in adolescents with delayed diagnosis of vertically acquired HIV infection.  55:145-152. 2012

Safety and efficacy of WC2031 versus vibramycin for the treatment of uncomplicated urogenital chlamydia trachomatis infection: A randomized, double-blind, double-dummy, active-controlled, multicenter trial.  55:82-88. 2012

Acquired epidermodysplasia verruciformis due to multiple and unusual HPV infection among vertically-infected, HIV-positive adolescents in Zimbabwe.  54. 2012

Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: A patient-level quantitative review of randomized trials.  54:1110-1122. 2012

Reply to Keynan.  54:1037-1038. 2012

Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: A randomized, placebo-controlled trial.  54:1013-1025. 2012

Differential occurrence of Streptococcus pneumoniae serotype 11E between asymptomatic carriage and invasive pneumococcal disease isolates reflects a unique model of pathogen microevolution.  54:794-799. 2012

Patient reported outcomes in routine care: Advancing data capture for HIV cohort research.  54:141-147. 2012

Diagnosis and management of uncomplicated chlamydia trachomatis infections in adolescents and adults: Summary of evidence reviewed for the 2010 centers for disease control and prevention sexually transmitted diseases treatment guidelines.  53. 2011

Interventions to prevent sexually transmitted infections, including HIV infection.  53. 2011

Sexually transmitted infections among women who have sex with women.  53. 2011

Trichomonas vaginalis genital infections: Progress and challenges.  53. 2011

Essential components of effective HIV care: A policy paper of the HIV medicine association of the infectious diseases society of america and the ryan white medical providers coalition.  53:1043-1050. 2011

HIV now firmly established in the middle ages.  53:1140-1142. 2011

Predictors of serological cure and serofast state after treatment in HIV-negative persons with early syphilis.  53:1092-1099. 2011

The spectrum of engagement in HIV care: Do more than 19%of HIV-infected persons in the US have undetectable viral load?.  53:1168-1169. 2011

Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy.  53:927-935. 2011

Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.  53:807-816. 2011

Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort.  53:826-835. 2011

Serologically confirmed household transmission of 2009 pandemic influenza a (H1N1) virus during the first pandemic wave - New York City, april-may 2009.  53:455-462. 2011

Ocular manifestations of candidemia.  53:262-268. 2011

Erratum: High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy (Clinical Infectious Diseases (2011) 52 (378-386)).  52:1200. 2011

Comparative effectiveness and toxicity of statins among HIV-infected patients.  52:387-395. 2011

High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy.  52:378-386. 2011

Low vitamin D among HIV-infected adults: Prevalence of and risk factors for low vitamin D levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the us general population.  52:396-405. 2011

NK cells, innate immunity and hepatitis C infection after liver transplantation.  52:369-377. 2011

Health care system and policy factors influencing engagement in HIV medical care: Piecing together the fragments of a fractured health care delivery system.  52. 2011

Re-evaluating the treatment of nongonococcal urethritis: Emphasizing emerging pathogens - A randomized clinical trial.  52:163-170. 2011

Epidemiology of 2009 pandemic influenza a (H1N1) deaths in the United States, April-July 2009.  52. 2011

Slowly progressive annular skin lesions in an elderly patient..  52. 2011

Reply to Johnson and Stricker.  51:1109-1110. 2010

Bone disease in HIV infection: A practical review and recommendations for HIV care providers.  51:937-946. 2010

Uncompensated medical provider costs associated with prior authorization for prescription medications in an HIV clinic.  51:718-724. 2010

How do HIV elite controllers do what they do?.  51:239-241. 2010

Reply to Hoenigl et al.  51:254-255. 2010

Factors associated with mortality in transplant patients with invasive aspergillosis.  50:1559-1567. 2010

Late presentation for human immunodeficiency virus care in the United States and Canada.  50:1512-1520. 2010

Causes of death in HIV-1-Infected patients treated with antiretroviral therapy, 1996-2006: Collaborative analysis of 13 HIV cohort studies.  50:1387-1396. 2010

Invasive fungal infections among organ transplant recipients: results of the transplant-associated infection surveillance network (Transnet).  50:1101-1111. 2010

Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the transplant- associated infection surveillance network (TRANSNET) database.  50:1091-1100. 2010

Routine, self-administered, touch-screen, computer-based suicidal ideation assessment linked to automated response team notification in an HIV primary care setting.  50:1165-1173. 2010

Erratum: Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. (Clinical Infectious Diseases (2009) 49:(1-45)).  50:1079. 2010

Blastomycosis of the central nervous system: A multicenter review of diagnosis and treatment in the modern era.  50:797-804. 2010

Sex and gender differences in travel-associated disease.  50:826-832. 2010

Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.  50:912-919. 2010

Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine care.  50:574-584. 2010

Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America.  50:291-322. 2010

Cryptococcosis in the developing world: An elephant in the parlor.  50:345-346. 2010

Erratum: Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. (Clin Infect Dis (2009) 49 (1-45)).  50:457. 2010

Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of age.  50:221-228. 2010

Obesity and dyslipidemia in behaviorally HIV-infected young women: Adolescent trials network study 021.  50:106-114. 2010

Reply to Collins et al and Manian.  49:1771-1772. 2009

Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America.  49:1582-1590. 2009

Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: A prospective multicenter study.  49:931-934. 2009

Birth prevalence and natural history of congenital cytomegalovirus infection in a highly seroimmune population.  49:522-528. 2009

Reply to kontoyiannis.  49:639-640. 2009

Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the infectious diseases society of America.  49:1-45. 2009

A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis.  48:1775-1783. 2009

HIV policy: The path forward- A joint position paper of the HIV medicine association of the infectious diseases society of America and the American College of physicians.  48:1335-1344. 2009

Variable Impact on Mortality of AIDS-Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS-Defining Conditions Are Created Equal.  48:1138-1151. 2009

Incomplete peripheral CD4⁺ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment.  48:787-794. 2009

Clinical practice guidelines for the management of candidiasis: 2009 Update by the Infectious Diseases Society of America.  48:503-535. 2009

Missed visits and mortality among patients establishing initial outpatient HIV treatment.  48:248-256. 2009

Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria.  47:674-683. 2008

Cost-effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries.  47:487-495. 2008

The management of encephalitis: Clinical practice guidelines by the Infectious Diseases Society of America.  47:303-327. 2008

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis (Clinical Infectious Diseases (2007) 45, (883-893)).  47:302. 2008

Clinical practice guidelines for the management of blastomycosis: 2008 Update by the infectious diseases society of America.  46:1801-1812. 2008

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.  46:1813-1821. 2008

Lactational amenorrhea as a risk factor for group a streptococcal vaginitis.  46. 2008

Clinical inertia in the management of low-density lipoprotein abnormalities in an HIV Clinic.  46:1315-1318. 2008

High sensitivity of human leukocyte antigen-B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.  46:1111-1118. 2008

Seasonal and pandemic influenza: A 2007 update on challenges and solutions.  46:1024-1031. 2008

Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006.  46:625-633. 2008

Reply to Eiland et al..  46:641. 2008

Matched-sample analysis: Sensitivity, specificity, and P values.  46:474-475. 2008

Reply to Connor.  46:476-477. 2008

Opt-out testing: Who can afford to take care of patients with newly diagnosed HIV infection?.  45. 2007

Clinical practice guidelines for the management of sporotrichosis: 2007 Update by the Infectious Diseases Society of America.  45:1255-1265. 2007

Expanding the spectrum of pathogens in urethritis: Implications for presumptive therapy?.  45:872-874. 2007

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.  45:883-893. 2007

The incidence and severity of herpes simplex encephalitis in Sweden, 1990-2001.  45:881-882. 2007

Nucleoside reverse-transcriptase inhibitor dosing errors in an outpatient HIV clinic in the electronic medical record era.  45:658-661. 2007

Persistence of nevirapine in breast milk after discontinuation of treatment.  45:391-394. 2007

Failure to establish HIV care: Characterizing the "no show" phenomenon.  45:127-130. 2007

Management of uncomplicated Chlamydia trachomatis infections in adolescents and adults: Evidence reviewed for the 2006 centers for disease control and prevention sexually transmitted diseases treatment guidelines.  44. 2007

Management of women with cervicitis.  44. 2007

HIV infection presenting in older children and adolescents: A case series from Harare, Zimbabwe.  44:874-878. 2007

Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population.  44:726-734. 2007

Reply to Behrens et al. [4].  44:762-763. 2007

Factors associated with seronegative chronic hepatitis C virus infection in HIV infection.  44:577-583. 2007

A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis.  44:213-219. 2007

Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients.  44:245-249. 2007

Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings?.  44:135-138. 2007

Recommendations for the management of herpes zoster.  44. 2007

Trichomonas vaginalis infection in male sexual partners: Implications for diagnosis, treatment, and prevention.  44:13-22. 2007

Trichomonas vaginalis infection: The most prevalent nonviral sexually transmitted infection receives the least public health attention.  44:23-25. 2007

The practice of travel medicine: Guidelines by the infectious diseases society of America.  43:1499-1539. 2006

Which policy to ADAP-T: Waiting lists or waiting lines?.  43:1365-1367. 2006

Recurrent benign lymphocytic meningitis.  43:1194-1197. 2006

Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.  43:1135-1142. 2006

Clinical research in the lay press: Irresponsible journalism raises a huge dose of doubt.  43:1031-1039. 2006

Reply to Tong et al. [4].  43:542-544. 2006

Invasive fungal pathogens: Current epidemiological trends.  43. 2006

Antifungal therapy: Lessons learned over the past 27 years.  42:1289-1296. 2006

Distribution of health care expenditures for HIV-infected patients.  42:1003-1010. 2006

Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials.  42:870-877. 2006

Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: An adult AIDS clinical trials group study.  42:401-407. 2006

Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus.  42:126-131. 2006

Family outbreaks of invasive community-associated methicillin-resistant Staphylococcus aureus infection..  42. 2006

Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.  41:1326-1332. 2005

Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons.  41:1045-1048. 2005

Multicenter clinical evaluation of the (1→3) β-D-glucan assay as an aid to diagnosis of fungal infections in humans.  41:654-659. 2005

Trends in cancer incidence rates among HIV-infected patients [3] (multiple letters).  41:124-127. 2005

Risk of congenital cytomegalovirus infection [2] (multiple letters).  40:1701-1703. 2005

The use of dexamethasone in bacterial meningitis [2] (multiple letters).  40:1061-1063. 2005

Human herpesvirus 6 infection of the central nervous system: Is it just a case of mistaken association?.  40:894-895. 2005

Managing cryptococcal meningitis is about handling the pressure.  40:480-482. 2005

Seroprevalence of anti-H5 antibody among Thai health care workers after exposure to avian influenza (H5N1) in a tertiary care center..  40. 2005

Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America.  39:1307-1313. 2004

Practice guidelines for the management of bacterial meningitis.  39:1267-1284. 2004

Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002.  39:1380-1384. 2004

Clinical and therapeutic management of pulmonary Mycobacterium xenopi infection in HIV-positive patients [3] (multiple letters).  38:1642-1644. 2004

Anemia in HIV infection: Clinical impact and evidence-based management strategies.  38:1454-1463. 2004

Antiretroviral drug content in products from developing countries.  38:1317-1319. 2004

Interval between births and risk of congenital cytomegalovirus infection.  38:1035-1037. 2004

Guidelines for Treatment of Candidiasis.  38:161-189. 2004

Donor-Related Coccidioidomycosis in Organ Transplant Recipients.  37:1265-1269. 2003

Human Immunodeficiency Virus Type 1-Related Pulmonary Mycobacterium xenopi Infection: A Need to Treat?.  37:1250-1254. 2003

A prospective observational study of candidemia: Epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.  37:634-643. 2003

Duration of highly active antiretroviral therapy regimens.  37:714-722. 2003

Prophylaxis against dialysis catheter-related bacteremia with a novel antimicrobial lock solution.  36:1539-1544. 2003

A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.  36:1221-1228. 2003

Methods for integration of pharmacokinetic and phenotypic information in the treatment of infection with human immunodeficiency virus.  36:373-377. 2003

A prospective study of genital herpes simplex virus type 2 infection in human immunodeficiency virus type 1 (HIV-1)-seropositive women: Correlations with CD4 cell count and plasma HIV-1 RNA level.  36:207-211. 2003

Comparative analysis of commercial assays for the detection and quantification of human immunodeficiency virus type 1 (HIV-1) RNA in plasma from patients infected with HIV-1 subtype C.  35:323-325. 2002

Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: A report of 12 cases.  33:1914-1921. 2001

The impact of culture isolation of Aspergillus species: A hospital-based survey of aspergillosis.  33:1824-1833. 2001

Distribution of Pneumocystis carinii f. sp. hominis types in the lung of a child dying of Pneumocystis pneumonia.  33:100-102. 2001

Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy.  33:690-699. 2001

Invasive mold infections in allogeneic bone marrow transplant recipients.  32:1319-1324. 2001

Multicenter case-control study of risk factors for histoplasmosis in human immunodeficiency virus-infected persons.  32:1215-1220. 2001

Internet and computer-based resources for travel medicine practitioners.  32:757-765. 2001

Influence of the normal menstrual cycle on vaginal microflora [6].  32:325. 2001

Reply to Dr. Chandrasekar (Clin Infect Dis 2001; 32: 320-1) and Drs. Marr and Boeckh (Clin Infect Dis 2001; 32: 321) [1].  32:518-519. 2001

Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors.  30. 2000

A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficieney virus-infected individuals.  30:540-544. 2000

Introduction to antifungal drugs..  30:653-657. 2000

Candiduria: A randomized, double-blind study of treatment with fluconazole and placebo.  30:19-24. 2000

Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis.  30:47-54. 2000

Sporotrichosis in Peru: Description of an area of hyperendemicity.  30:65-70. 2000

Antibiotic susceptibility profiles for group B streptococci isolated from neonates, 1995-1998.  31:76-79. 2000

Practice guidelines for the management of cryptococcal disease.  30:710-718. 2000

Practice guidelines for the management of patients with blastomycosis.  30:679-683. 2000

Practice guidelines for the treatment of candidiasis.  30:662-678. 2000

Prolonged suppression of human immunodeficiency virus type 1 RNA during dual nucleoside reverse-transcriptase-inhibitor therapy in clinical practice.  31:1095-1097. 2000

Refractory mucosal candidiasis in advanced human immunodeficiency virus infection.  30:749-756. 2000

Screening for latent tuberculosis in sexually transmitted disease clinics [4].  30:986. 2000

Serological survey and active surveillance for La Crosse virus infections among children in Tennessee.  31:1284-1287. 2000

A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group..  28:291-296. 1999

A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis.  28:291-298. 1999

Carriage of multidrug-resistant Streptococcus pneumoniae and impact of chemoprophylaxis during an outbreak of meningitis at a day care center.  29:1257-1264. 1999

Newly recognized focus of La Crosse encephalitis in Tennessee.  28:93-97. 1999

Herpes simplex viruses.  26:541-555. 1998

Vertebral blastomycosis with paravertebral abscess: Report of eight cases and review of the literature.  26:413-418. 1998

An outbreak of multidrug resistant pneumococcal meningitis in a day care center.  25:361. 1997

Capsular polysaccharide types of group b streptococcal isolates from neonates wtth early-onset systemic infection.  25:439. 1997

Changing frequency of early-onset group B streptococcal disease(EOGBS) in neonates from 1992 to 1996.  25:409. 1997

Cryptococcosis in non-HIV infected patients: A multicemer survey.  25:379. 1997

Current trends in nosocomial candidemia: Results of a large multienter study.  25:357. 1997

Effects of primary maternal cmv infection on early pregnancy and the immature placenta in guinea pigs.  25:375. 1997

Long term virological and immunological effect of the HIV protease inhibitor, VIRACEPT® (nelfinavir mesylate, NFV) in combination with zidovudine (AZT) and lamivudine (3TC).  25:396. 1997

Treatment of blastomycosis with higher doses of fluconazole. The National Institute of Allergy and Infectious Diseases Mycoses Study Group..  25:200-205. 1997

Cardiac arrhythmias associated with coadministration of azole compounds and cisapride [4] (multiple letters).  24:1285. 1997

Treatment of blastomycosis with higher doses of fluconazole.  25:200-205. 1997

Fluconazole therapy for histoplasmosis. The National Institute of Allergy and Infectious Diseases Mycoses Study Group..  23:996-1001. 1996

Fluconazole therapy for histoplasmosis.  23:996-1001. 1996

Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: A meta-analysis of placebo-controlled trials.  22:341-347. 1996

Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole.  22:46-50. 1996

Update on the management of onychomycosis: Highlights on the Third Annual International Summit on Cutaneous Antifungal Therapy.  23:305-313. 1996

Herpes zoster in patients with human immunodeficiency virus infection--an ever-expanding spectrum of disease..  21:989-990. 1995

Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group..  21:994-996. 1995

Treatment of blastomycosis with fluconazole: a pilot study. The National Institute of Allergy and Infectious Diseases Mycoses Study Group..  20:267-271. 1995

Editorial response: Herpes zoster in patients with human immunodeficiency virus infection–an ever-expanding spectrum of disease.  21:989-990. 1995

Editorialresponse: Clinical and host differences between infections with the two varieties of cryptococcus neoformans.  21:35-36. 1995

Guidelines for the prevention and treatment of B-virus infections in exposed persons.  20:421-439. 1995

Herpes simplex virus infections of the central nervous system: Therapeutic and diagnostic considerations.  20:414-420. 1995

Herpesvirus infections in persons infected with human immunodeficiency virus.  21. 1995

Human herpesvirus 6 is associated with focal encephalitis.  21:571-576. 1995

Intravascular catheter exchange and duration of candidemia.  21:994-996. 1995

Pentamidine Concentrations in a Mother with AIDS and in Her Neonate.  20:1569-1570. 1995

Treatment of blastomycosis with fluconazole: A pilot study.  20:267-271. 1995

USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: Disease-specific recommendations.  21. 1995

Diagnosing neurosyphilis..  18:295-297. 1994

Editorial response: Diagnosing neurosyphilis.  18:295-297. 1994

Human immunodeficiency virus infection.  18:963-973. 1994

Intraocular blastomycosis: Case report and review.  18:805-807. 1994

Measurement of cryptococcal antigen in serum and cerebrospinal fluid: Value in the management of aids-associated cryptococcal meningitis.  18:789-792. 1994

Pulmonary infection due to legionella cincinnatiensis in renal transplant recipients: Two cases and implications for laboratory diagnosis.  18:385-389. 1994

Evaluation of new anti-infective drugs for the treatment of infection with human immunodeficiency virus.  17:794-801. 1993

Evaluation of new anti-infective drugs for the treatment of infection with human immunodeficiency virus. The European Working Party of the European Society of Clinical Microbiology and Infectious Diseases..  17:794-801. 1993

Radiographic Changes Associated with Tracheal Isolation of Ureaplasma Urealyticum from Neonates.  17:S122-S130. 1993

Systemic Neonatal Infection Due to Ureaplasma urealyticum.  17:S131-S135. 1993

Therapeutic Considerations for Ureaplasma urealyticum Infections in Neonates.  17:S208-S214. 1993

Evaluation of new anti-infective drugs for the treatment of acute bacterial meningitis. Infectious Diseases Society of America and the Food and Drug Administration..  15 Suppl 1:S182-S188. 1992

Evaluation of new anti-infective drugs for the treatment of cryptococcal meningitis. Infectious Diseases Society of America and the Food and Drug Administration..  15 Suppl 1:S189-S194. 1992

Evaluation of new anti-infective drugs for the treatment of toxoplasma encephalitis. Infectious Diseases Society of America and the Food and Drug Administration..  15 Suppl 1:S200-S205. 1992

Evaluation of new anti-infective drugs for the treatment of viral encephalitis. Infectious Diseases Society of America and the Food and Drug Administration..  15 Suppl 1:S195-S199. 1992

Evaluation of new anti-infective drugs for the treatment of acute bacterial meningitis.  15:S182-S188. 1992

Evaluation of new anti-infective drugs for the treatment of cryptococcal meningitis.  15:S189-SI94. 1992

Evaluation of new anti-infective drugs for the treatment of toxoplasma encephalitis.  15:S200-S205. 1992

Evaluation of new anti-infective drugs for the treatment of viral encephalitis.  15:S195-S199. 1992

Geographic Distribution of Penicillin-Resistant Clones of Streptococcus pneumoniae: Characterization by Penicillin-Binding Protein Profile, Surface Protein A Typing, and Multilocus Enzyme Analysis.  15:112-118. 1992

The management of pregnancies complicated by genital infections with herpes simplex virus.  15:1031-1038. 1992